SRT Therapeutics, San Diego, CA, Onsite
The Associate Director, Biologics CMC is a technical contributor responsible for supporting biologics development from upstream cell culture and process development through drug product readiness, clinical supply, and regulatory submission. This role provides technical input for large molecule programs, including monoclonal antibodies, fusion proteins, and related biologic modalities, while partnering closely with Process Development, Analytical Development, Quality, Regulatory, Clinical Operations, and external CDMOs.
Hybrid
SRT Therapeutics is a San Diego-based biotech company established in 2024 by the founders of Prometheus Biosciences, Steph Targan, MD (Cedars Sinai), Janine Bilsborough, Ph.D. (Cedars Sinai), the scientific team that discovered Tulisokibart (MK7240) and the role of TL1A in IBD and Scott Glenn and Lauren Otsuki, the drug development team that took Tulisokibart (MK7240) from academia into the clinic. Building on the demonstrated success of the precision medicine approach in IBD with Tulisokibart, SRT Therapeutics will expand this approach by targeting key pathways that not only modulate inflammatory pathways, but also promote tissue healing in IBD. This strategy will move SRT Therapeutics beyond the current empirical treatment model to realize the goal of enhancing both outcomes and the quality of care for our patients.
View company profile →